Arrowhead Halts its ARO-ENaC Phase 1/2 Clinical Trial Arrowhead Pharmaceuticals recently notified about its voluntary decision to put a pause on its ongoing Phase 1/2 clinical study of ARO-ENaC for patients with cystic fibrosis (CF). The announcement came after a preliminary update from an ongoing chronic ...Find More
Novavax targets approval for the COVID-19 vaccine in the US Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The aim hints the U.S. could join the U.K. on the list of countries to permit the vaccine in the first half of the year. The vaccine’s success in a 15,000-sub...Find More
Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...Find More
Olema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in other areas. The capital will bankroll a phase 1/2 study of the asset, OP-1250, as a single agent. Olema Oncology will a...Find More
AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...Find More
Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBC Immunomedics- a New Jersey-based pharmaceutical company has announced to freeze its Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan aimed at treating metastatic triple-negative brea...Find More
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.